

protea®



Morgantown, West Virginia



West Virginia Biosciences Association
April 21 2015




Our business: molecular information

We improve the quality, timeliness, and comprehensiveness of molecular information – critical to the management of all life science research and diagnostic medicine

Better molecular information improves research productivity and treatment outcomes

We identify molecules produced by cells directly, more than ten times faster than current methods.






The need for cell-based molecular information

Understanding the interplay of the molecules produced by cells is key to:

- Understanding the molecular basis of diseases
- Improved patient outcomes
- Improved R&D Productivity ("Fail early, fail cheap")
- New Basic Discoveries





Protea: A revolutionary life sciences franchise

Protea is the commercial leader in the field of mass spec imaging

Developed and launched proprietary, disruptive technology platform that identifies hundreds of molecules in seconds to minutes.

Validated technology – 10 issued patents, >40 peer-reviewed publications

Commenced offering the first commercial services for mass spectrometry imaging



Our Management Team


Name & Title	Background
Stephen Turner Founder, CEO	 Founded OncorMed (Gene Logic) that developed genomic breast cancer panels Founded Quorum Sciences (Sold to Vertex) Founded Bethesda Research Laboratories (BRL) (Life Technologies)
Stanley Hostler Co-Founder & Director	 Prominent West Virginia Attorney, Founder of HISTA Program, WVU and MBRCC supporter
Greg Kilby, PhD. Vice Pres., Operations	 Director, North American Applications Laboratories, Thermo Fisher Manager, Applications Laboratory, Agilent & Pfizer R&D
Matthew Powell, Ph.D. Chief Science Officer Vice President, R&D	 Ph.D. from West Virginia University Developed and holds patents on technology
Steve O'Loughlin VP, Corp. Finance & Development	 Business Development, Caliber I.D. (fka Lucid, Inc.) Healthcare Investment Banking, Jesup & Lamont
David Halverson Director, Business Development	 Exec. Director, Key Accounts for MPI Research Head, U.S. Sales, Huntingdon Life Sciences Dir. North America Bus. Dev,, Quintiles



40 employees 10 PhD scientists


LAESI: A revolutionary molecular information platform

Front End - Instrument



- Analyzes biological samples with no sample prep
- Molecules are immediately sent into mass spectrometer for analysis
- Patents extend through 2026

Back End – Software/Data Analytics



- Analyzes data to create images of molecules and their location
- Generates 2D or 3D images of 1000+ of molecules per analysis
- Developed in house, fully supported by Protea




LAESI: A revolutionary molecular information platform


- ✓ Universal Analyzes virtually all biological sample types including living cells
- ✓ **Powerful** 1000+ of distinct molecules per analysis
- ✓ Speed Data capture in seconds to minutes
- ✓ Comprehensive Detects proteins, peptides, lipids & small molecules simultaneously
- ✓ Big Data Several gigabytes of data from a single sample.
- ✓ Versatile 2D & 3D imaging capabilities
- ✓ Ease No sample preparation required



Tissue Samples



3D Engineered
Tissues



Living Cell/
Bacterial Colonies



Plants/ Natural Products



Medical Devices/
Biomaterials




The Offering Documents consist of the Private Placement Memorandum, Unit Purchase Agreement, Subscription Agreement, Form of Warrant and Registration Rights Agreement. This document not not constitute an offering document. Potential investors or shareholders should not rely on the information contained in this document before making an investment decision. This document has been prepared for informational purposes only. This document, including the information contained in this disclaimer, does not constitute an offer, invitation or recommendation to subscribe for or purchase any security and neither the document, disclaimer nor anything contained in them forms the basis of any contract or commitment. This presentation does not purport to summarize all information that an investor should consider when making an investment decision. It should be read in conjunction with the Offering Documents.

LAESI 3D molecular imaging

Generating molecular data from complex samples


- Direct 3D image of molecules from a contact lens
- Laser "drills" into samples directly, no sample prep
- No other technology can provide this solution



Source: The Company




LAESI: A revolutionary molecular information platform





Protea addresses large markets where new capabilities are needed





Source: http://www.marketsandmarkets.com/Market-Reports/tissue-diagnostics-market-1063949.html

Source: http://www.marketsandmarkets.com/PressReleases/molecular-diagnostic.asp

A History of Value Creation

LAESI Instruments Licensed LAESI technology from George Washington University Licensed LAESI technology to market

for Clinical Applications Proprietary



Services


Launched proprietary services, expanded team and infrastructure

Collaborations
for Clinical



Launched first
collaboration with
MSKCC & Dana-Farber
– Followed by
collaboration with Yale
University

Proprietary Consumable Products



REDIchip resulting from DARPA Grant (GE, Stanford Research) launched in Q1 2015

2008 2010 2012 2013 2014 2015 2016



The Offering Documents consist of the Private Placement Memorandum, Unit Purchase Agreement, Subscription Agreement, Form of Warrant and Registration Rights Agreement. This document focus not constitute an offering document. Potential investors or shareholders should not rely on the information contained in this document before making an investment decision. This document has been prepared for informational purposes only. This document, including the information contained in this disclaimer, does not constitute an offer, invitation or recommendation to subscribe for or purchase any security and neither the document, disclaimer nor anything contained in them forms the basis of any contract or commitment. This presentation does not purport to summarize all information that an investor should consider when making an investment decision. It should be read in conjunction with the Offering Documents.

Technology Validation and Market Adoption

Awards







Collaborators

















































Key Business Objectives







Advance technology into clinical medicine


Rapidly expand addressable markets

Remain commercial technology leader through continued innovation – LAESI 2.0



The Offering Documents consist of the Private Placement Memorandum, Unit Purchase Agreement, Subscription Agreement, Form of Warrant and Registration Rights Agreement. This document focus not constitute an offering document. Potential investors or shareholders should not rely on the information contained in this document before making an investment decision. This document has been prepared for informational purposes only. This document, including the information contained in this disclaimer, does not constitute an offer, invitation or recommendation to subscribe for or purchase any security and neither the document, disclaimer nor anything contained in them forms the basis of any contract or commitment. This presentation does not purport to summarize all information that an investor should consider when making an investment decision. It should be read in conjunction with the Offering Documents.

Market Expansion




The Offering Documents consist of the Private Placement Memorandum, Unit Purchase Agreement, Subscription Agreement, Form of Warrant and Registration Rights Agreement. This document over not constitute an offering document. Potential investors or shareholders should not rely on the information contained in this document before making an investment decision. This document has been prepared for informational purposes only. This document, including the information contained in this disclaimer, does not constitute an offer, invitation or recommendation or subscribe for or purchase any security and neither the document, disclaimer nor anything contained in them forms the basis of any contract or commitment. This presentation does not purport to summarize all information that an investor should consider when making an investment decision. It should be read in conjunction with the Offering Documents.

Experiencing strong growth in our key business segments



Most Recent Quarterly Performance

Year to Date Performance



Source: Company SEC filings and internal calculations



Corporate Development: Collaboration with MSKCC and DFCI



Dr. Andre Moriera
Pathologist
MSKCC



Dr. Robert Downey
Surgeon
MSKCC



Dr. Franziska Michor Biostatistician Dana-Farber

protea

Protea Enters Into Collaborative Research Agreement With the Memorial Sloan-Kettering Cancer Center and the Dana-Farber Cancer Institute


LAESI(R) Technology to be Used to Profile Cancer Cells to Improve Diagnosis and Treatment Selection







Collaboration with Insphero AG



Lipid profiles
of Insphero 3D
Microtissues,
generated by
Protea, using
proprietary
LAESI mass
spec imaging
technology

Top right –
note lipid not
present in
necrotic core—
only seen in
biologically
active part of
tumor
microtissue



Unmatched Capabilities



- Disruptive technology meeting researchers' need for better data.
- Groundbreaking collaborations with leading institutions
- Expanding list of industries adopting Protea technologies







Preclinical R&D













Biomarker
Discovery/Diagnostics/C
linical

AgBio/MedTech/Others



Protea: A molecular information franchise





Protea's mass spectrometry imaging laboratory

- Market leader growing revenue and customer base
- Proprietary molecular imaging platform rapid, fully-automated
- Innovative business model for near and long term revenue growth
- Developing an entire new class of tests for cancer diagnosis



• Be yourself

- Be yourself
- Believe in what you are saying

- Be yourself
- Believe in what you are saying
- Brevity less is more

- Be yourself
- Believe in what you are saying
- Brevity less is more
- A two way street listen

- Be yourself
- Believe in what you are saying
- Brevity less is more
- A two way street listen
- Evolve your presentation

- Be yourself
- Believe in what you are saying
- Brevity less is more
- A two way street listen
- Evolve your presentation
- Have fun